GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Arqule, Inc. (ARQL) [hlAlert]

ArQule, Inc. is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Company's targeted, broad-spectrum products and research programs are focused on key biological processes that are central to cancer. ArQule's lead clinical-stage products have been generated
from two scientific platforms: Cancer Survival Protein modulation and Activated Checkpoint Therapy. The Cancer Survival Protein modulation platform has generated a clinical-stage product that mediates its effects by inhibiting the activity of a molecule known as c-Met, which plays multiple roles in cancer cell growth, survival, invasion, angiogenesis and metastasis. The ACT platform is designed to kill cancer cells selectively while sparing normal cells through direct activation of DNA damage response/checkpoint pathways. The Company's lead ACT program, based on the E2F-1 pathway, is partnered with Roche.
( Total: 16 Current Stock Recommendations )
Arqule, Inc.   (16)
Hold 31% Buy 69%
Related companies
China Biologic ...   (4)
Buy 100%
ATHERSYS INC   (7)
Buy 100%
ACURA PHARMACEUTICAL   (2)
Buy 100%
BioSpecifics ...   (5)
Buy 100%
Derma Sciences, Inc.   (2)
Buy 100%
Tenax Therapeutics ...   (2)
Buy 100%
ARCA BIOPHARMA INC.   (1)
Buy 100%
PROLOR Biotech, Inc.   (5)
Buy 100%
Opko Health Inc   (2)
Buy 100%
Nutraceutical ...   (1)
Buy 100%
Filter by Gains:   
  
Rating:
Buy ARQL
down 78.00 %

Rating:
Hold ARQL
Arqule, Inc. (ARQL) rated Mkt Perform by Leerink Partners
Wednesday,  Dec 9, 2015  10:25 AM ET

Rating:
Hold ARQL

Rating:
Hold ARQL
down 14.84 %
Arqule, Inc. (ARQL) downgraded to Neutral by Citigroup
Wednesday,  Sep 18, 2013  8:25 AM ET

Rating:
Hold ARQL
Arqule, Inc. (ARQL) rated Hold with price target $3 by MLV & Co
Friday,  May 24, 2013  2:25 PM ET

Rating:
Hold ARQL

Rating:
Buy ARQL
down 14.84 %
Arqule, Inc. (ARQL) rated Buy by Citigroup
Friday,  Oct 26, 2012  8:25 AM ET

Rating:
Hold ARQL
down 65.19 %
Arqule, Inc. (ARQL) downgraded to Hold by Needham
Tuesday,  Oct 2, 2012  3:25 PM ET

Rating:
Buy ARQL
down 68.68 %

Rating:
Buy ARQL
down 65.19 %
Arqule, Inc. (ARQL) rated Buy by Needham
Monday,  Jul 30, 2012  8:25 AM ET

Rating:
Buy ARQL
down 76.02 %

Rating:
Buy ARQL
down 78.00 %

Rating:
Buy ARQL
down 73.65 %

Rating:
Buy ARQL
down 69.65 %

Rating:
Buy ARQL
up 27.23 %
Arqule, Inc. (ARQL) upgraded to Buy by UBS
Tuesday,  Oct 13, 2009  8:25 AM ET

Your Recent Stocks
SymbolLastChange
ARQL 1.57 down  -10.79 %

RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy